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Rapid removal of DFO-chelated aluminum during hemodialysis using
polysulfone dialyzers. Aluminum (Al) removal following deferoxamine
(DFO) therapy in hemodialysis patients was evaluated in a paired-
fashion comparing cuprophane (Travenol 12.11) and polysulfone
(Fresenius F-80) dialyzers. QB and QD were held constant at 250 and
500 mI/mm, respectively. The polysulfone dialyzer increased total
plasma Al clearance from 20.0 2.8 to 80.5 7.6 mI/mm (P < 0.01),
and reduced the t 1/2 of plasma Al during hemodialysis from 538 113
to 112 12 mm (P < 0.01). The polysulfone F-80 dialyzer increased Al
removal during the first hour of hemodialysis from 518 191 to 1812
720 pg/hr (P < 0.01). During a four hour hemodialysis the F-80 dialyzer
returned plasma Al levels to pre-DFO values (103 36 vs. 93 23, P
<0.05), suggesting complete removal of the DFO chelated Al complex.
In one patient Al removal was evaluated using cuprophane, F-40, F-60
and F-80 dialyzers and the t 1/2 for Al removed decreased from 484.6 to
276.1 and 108 to 99 minutes, respectively. These data show the
Fresenius F-80 polysulfone dialyzer effects the rapid removal of DFO-
Al complexes. We propose use of the Fresenius F-80 dialyzer in
conjunction with reduced DFO doses and i.m. administration of DFO
the day prior to dialysis to limit DFO exposure as a method to decrease
DFO-related side-effects in hemodialysis patients.
Aluminum (Al) accumulation in patients with end-stage renal
disease has been associated with a number of clinical problems
including encephalopathy [1, 2], osteomalacia [3, 4] and anemia
[5]. Removal of Al from these patients is difficult due to its large
volume of distribution, high protein binding, and poor dialyz.
ability. Deferoxamine (DFO), a trivalent metal chelating agent,
has been used successfully to remove milligram quantities of Al
during hemodialysis [3, 6—91. DFO therapy, however, has many
recently described potential side-effects including ocular toxic-
ity [10, 11], auditory neurotoxicity [11], thrombocytopenia [12],
and an increased potential for septicemia [13—15]. Since these
potential side-effects appear to at least in part be dose and
duration related [10, 11] it has become essential to minimize a
patient's exposure to DFO,
Two recent reports [9, 16] indicate that only 25 to 30% of the
DFO chelated Al is removed during a standard four-hour
dialysis. Therefore, hemodialysis patients treated with DFO
maintain high serum levels of DFO chelated complexes for
extended periods of time. In an attempt to reduce this exposure
several authors have evaluated the efficacy of different dialyz-
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ers to remove the chelated complexes. Removal, however, has
remained low and not statistically different from cuprophane
membranes [17, 18]. The purpose of the present studies was,
therefore, to determine the ability of the polysulfone dialyzer to
remove DFO-chelated Al.
Methods
Nine patients on chronic hemodialysis were studied and of
these, three patients were studied in a paired fashion. Patients
enrolled in these studies had a mean initial serum Al level of 104
24 pjg/liter which increased to 402 154 gIliter in response
to 2 grams of DFO given intravenously. Two grams of DFO
(Desferal, Ciba Pharmaceutical Co., Summit, New Jersey,
USA) was administered intravenously 24 hours prior to dialysis
at the rate of 1 gram per hour using a volumetric infusion pump
(Imed model 927, Imed Corporation, San Diego, California,
USA). All blood samples were collected in heparinized tubes
(green top).
Studies were conducted on a Fresenius A 2008 C hemodial-
ysis machine with a blood flow rate of 250 ml per minute and a
bicarbonate dialysate (pH 7.2) flow rate of 500 ml per minute. In
all patients, either Travenol Model 12.11 or Clirans Model
TAFO8 and Fresenius Model F-80 dialyzers were used. Arterial
(predialyzer) and venous (post-dialyzer) samples were obtained
simultaneously at 0 to 4 hours for Al determinations.
Analytical procedures
Plasma Al levels were determined using flameless atomic
absorption as previously described [19]. Al clearance, volume
of distribution and the plasma Al t 1/2 during hemodialysis were
calculated as previously described [16] during the first two
hours of hemodialysis. Al clearances were calculated using
simultaneous A-V extraction values based on total plasma Al
levels and based on at least two clearance determinations. The
formula used was based on plasma clearance, as we have
previously shown Al is not removed from erythrocytes [161:
[(A-V)IA X QB X (100% — Hct%)]. Ultrafiltration rates were
not included in this calculation. Data are expressed as the mean
1 standard deviation and were analyzed using the Student's
I-test unless otherwise noted. P values less than <0.05 were
considered significant and were reported as either <0.05 or
<0.01.
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Fig. 1. The change in plasma aluminum (Al) levels during hemodialysis with the Travenol 12.11 cuprophane (closed symbols) and Fresenius F-80
polysulfone dialyzers (open symbols). A. The results from one patient with the pre-DFO plasma Al level indicated by pre. B. A semi-log plot of
plasma Al levels vs. time during hemodialysis for 3 patients studied in a paired fashion. The cross-hatched horizontal bar represents the mean
1 SD of pre-DFO plasma Al levels.
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Fig. 2. Al removal (p.g) during the first hour of hemodialysis using the
Travenol 12,11 cuprophane (•) and Fresenius F-80 polysulfone (0)
dialyzers in 3 patients studied in a paired fashion. Plasma Al levels
began (pre) and ended (1 hr hemodialysis) at 319 31 and 218 20 for
the F-80 studies and 292 26 and 263 26 for the 12.11 studies.
Results
Figure 1A shows the change in plasma Al over time during
dialysis in a representative patient using the Travenol Model
12.11 and Fresenius Model F-80 dialyzers. Although the cupro-
phane dialyzer resulted in reduced plasma Al levels, the Fresenius
dialyzer reduced plasma Al levels at a markedly increased rate,
especially during the first two hours. Figure lB shows the data
from three patients on the semi-log plot. The cuprophane
dialyzer resulted in a constant decrease in plasma Al during the
entire dialytic period. The Fresenius dialyzer, however, caused
the rapid decline in plasma Al during the first two hours, and
thereafter a much slower rate was observed in all patients. At
the end of the four hours of dialysis the arterial Al level for the
Table 1. Effect ofdifferent dialyzers on the cleara
plasma Al
nce and t 1/2 of
Membrane N
Al clearance
mI/mina
t 1/2"
mm
Curprophanec
Polysulfone F-80
P value
7
6
20.0 2,8d (7)
80.5 7.6 (6)
<0.01
538 113 (6)
112 12(3)
<0.01
a Plasma Al clearance was determined using at least two determina-
tions for A-V Al values with a QD of 500 mI/mm and a QB of250 mI/mm.
b For all membranes the t 1/2 was calculated during the first 2 hours
of hemodialysis and based on 4 or 5 plasma Al determinations with a
mean r value of 0.985 0.018.
C The TAFO8 and 12.11 cuprophane dialyzers were used in 3 and 4
patients, respectively. Al clearance was not statistically different for the
two cuprophane models used (20.4 1.5 vs. 19.5 4.4) and, therefore,
the data was combined.
"The data represent the mean SD of the number of individual
observations noted in the parenthesis (N).
cuprophane dialyzer was 215 33 pg/liter while that for the
Fresenius dialyzer was 103 36 pg/liter, a value not statisti-
cally different from the pre-DFO plasma Al value (93.3 22.6
pg/liter).
To quantitate differences in actual Al removal by the different
dialyzers, the quantity of Al removed was determined over the
first hour of dialysis and is shown in Figure 2. The polysulfone
F-80 dialyzer removed much larger quantities of Al during the
first hour of dialysis in all patients studied (1812 720 vs. 518
191 .tg/hr, P < 0.01). The gradient for Al removal of the F-80
and 12.11 dialyzers was not statistically different (319 31 vs.
292 26).
To quantitate the disappearance of plasma Al during hemo-
dialysis by the different dialyzers, the intradialytic t 1/2 for
plasma Al and clearance of plasma Al were calculated and are
shown in Table 1. The cuprophane dialyzers had a t 1/2 of 538
113 minutes which is in agreement with our previous study
[161. The polysulfone F-80 dialyzers, on the other hand, had a
markedly reduced t 1/2 of 112 12 minutes (P < 0.01). Plasma
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Fig. 3. A semi-log plot of plasma Al levels during hemodialysis using
the Travenol 12.11 cuprophane (•). Fresenius F-40 (A), F-60 (E) and
F-80 (0) dialyzers during the first 2 hours o.fhemodia!ysis.
Al clearance also increased more than fourfold increasing from
20.0 to 80.5 mllmin (P <0.01) with use of the F-80 polysulfone
dialyzer. While the clearance of chelated Al by cuprophane
dialyzer remained stable over time, Al clearance by the F-80
dialyzer decreased during the last two hours of dialysis. This
necessitated that t 1/2 and clearance values be determined
during the first two hours of dialysis.
In one patient the disappearance of plasma Al was quanti-
tated using the cuprophane, F-40, F-60, and F-80 dialyzers.
These data are shown in Figure 3 and indicate marked differ-
ences in plasma Al disappearance rate using the different
polysulfone dialyzers. For this patient the calculated intradi-
alytic t 1/2 of plasma Al reduction was 484.6, 276.1, 108.8, and
99 minutes for the cuprophane, F-40, F-60 and F-80 dialyzers,
respectively. In Figure 4, the effect of surface area on the
intradialytic t 1/2 of plasma Al is shown. Although the increased
surface area of the F-60 (1.25 m2) and F-80 (1.9 m2) polysulfone
dialyzers improved chelated Al removal, even the F-40
polysulfone dialyzer, with a surface area less than the
cuprophane dialyzer (0.65 vs. 0.80 m2), resulted in markedly
reduced plasma Al t 1/2 (276 vs. 485 mm).
Discussion
Al toxicity has become an important clinical problem in
patients with end-stage renal disease. Removal of excess Al
using DFO has been documented to reverse osteomalacia [6],
anemia [5] and encephalopathy [20]. However, long-term use of
DFO has been associated with dose and duration related
side-effects [10—15]. Unlike individuals with normal renal func-
tion who readily excrete DFO and its complexed metals, only
approximately 25 to 30% of the DFO-Al complex is cleared
during a standard hemodialysis [9, 16], putting dialysis patients
in a high risk group for potential DFO related complications.
Therefore, rapid removal of DFO chelated Al and iron during
dialysis would appear to be desirable in hemodialysis patients.
To cjate, however, improved removal of the DFO-Al complex
by using different dialyzers has met with only minimal or no
success [17, 181. Other investigators have used microencapsu-
lated active carbon to remove Al. While Al removal increased
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Fig. 4. The effect of su,face area of polysulfone dialyzers on DFO-
chelated A! re,noval. The intradialytic t 1/2 of Al removal was plotted
against dialyzer surface area (m2). All studies were done on the same
patient and the t 1/2 was calculated during the first 2 hours of
hemodialysis.
the efficiency of removal remained low due to rapid saturation
of Al binding sites [21]. We have also evaluated this latter
technique and observed rapid saturation of Al binding and
minimal Al removal (unpublished observations).
In the present studies we demonstrate that the polysulfone
F-80 dialyzer effects a much greater removal of the DFO-
chelated Al complexes. Al removal, as evaluated by Al clear-
ance, the intradialytic t 1/2 for plasma Al, and Al removal all
indicated the F-80 polysulfone dialyzer resulted in markedly
improved, DFO-chelated Al removal. Increasing surface area
within the polysulfone series resulted in increased plasma Al
removal as would be predicted [221. Factors other than surface
area, however, also played a role in the enhanced Al removal as
Al removal by the cuprophane dialyzer, with a surface area of
0.8 m2, was far less than would be expected for a polysulfone
dialyzer with a similar surface area (Fig. 4). In two studies,
dialysate Al was determined and compared to A-V clearance
data. In these studies, 96.5% of the A-V Al difference could be
recovered in the dialysate. These data indicate Al is being
extracted during dialysis and is not binding to the polysulfone
membrane. Al clearance, which was stable during use of the
cuprophane dialyzer, decreased with time when the polysulfone
F-80 dialyzer was used. This we believe was due to the rapid
removal of DFO-Al complexes as evidenced by the return of
plasma Al to baseline values during the intradialytic period.
Since plasma Al in the non-DFO-chelated patient (baseline
plasma Al) exists primarily bound to transferrin or albumin [3,
23] and therefore non-dialyzable, these data suggest most, if not
all, of the DFO-complexed Al was removed during one dialysis
session. However, in three patients treated with DFO, plasma
Al levels 24-hours post-F-80 hemodialysis increased 36 14
pg/liter. We believe, but cannot directly prove, this increase
was due to release of Al from a slowly equilibrating compart-
ment.
Al clearances in these studies were based on total plasma Al
values and not ultraliltratable Al. It is, therefore, not surprising
that our reported clearance values are somewhat less than Al
clearance values reported by others [17, 18] for ultrafiltratable
Al. However, since these were paired studies (Fig. 1 to 3) the
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magnitude of difference between the two dialyzers would
remain constant even if ultrafiltratable levels were used.
In an attempt to limit DFO exposure we have adopted three
approaches. The first two approaches deal with minimizing the
dose of DFO and the duration of DFO exposure. Clinically the
use of low dose DFO has been shown to be efficacious.
Kurokawa et a! [24] have shown that 0.5 grams of DFO per
week reduced DFO-related side-effects and was as effective as
2 grams per week in improving symptoms in patients with
presumed Al associated bone disease. We have shown that 1
gram of DFO is as efficacious as 2 grams for mobilizing body Al
stores [16]. In addition, the i.m. administration of DFO has
been found to be as efficacious in chelating Al as i.v. DFO [161.
Finally, the present study documents the fact that the DFO-Al
complex can be rapidly removed during dialysis using polysul-
fone membrane dialyzers. Therefore, the combination of low
dose DFO, 0.5 to 1.0 grams per week, given i.m. the night prior
to dialysis can be used to reduce interdialytic DFO exposure.
Subsequent dialysis performed with polysulfone membranes
will then effect maximal removal of DFO complexes and will
also minimize exposure to DFO metal complexes. This overall
approach should theoretically reduce the incidence of dose and
duration related side-effects including infections from orga-
nisms which use DFO-Fe complexes as a growth stimulating
factor. Clearly, use of the polysulfone F-80 dialyzer offers
maximal benefit when plasma Al levels increase to high levels
following DFO administration. This is generally seen during the
first several months of DFO therapy. Whether this combined
approach will reduce DFO-related side effects and have equal
clinical efficacy will require additional long-term studies.
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